AstraZeneca’s head of cancer research José Baselga dies at age of 61
AstraZeneca has confirmed that their Executive Vice President Oncology R&D, and member of Senior Executive Team, José Baselga has passed away.
Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca has confirmed that their Executive Vice President Oncology R&D, and member of Senior Executive Team, José Baselga has passed away.
The Superior Court of California, County of Los Angeles rejected all but one of Gilead’s arguments to dismiss the HIV/AIDS patients’ legal theories against the company’s TDF-based HIV/AIDS drug, that cause permanent damage tokidneys and bones.
Bristol-Myers Squibb will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan.…
M Pharmaceutical will continue develop a patented topical drug product for the treatment of female sexual dysfunction (FSD), as part…
The pharmaceutical industry is typically reluctant to talk about U.S. drug prices, generally the highest in the world due to a combination of market fragmentation and free market policies. But recent high-profile price hikes by Mylan NV, Turing Pharmaceuticals and Valeant Pharmaceuticals International have raised the ire of consumers and lawmakers.
U.S. Court of Appeals for the Federal Circuit has upheld the district court’s decision and ruled in the Eli Lilly’s favor regarding validity and infringement of the vitamin regimen patent for Alimta (pemetrexed for injection).
Joseph Gunnar & Co., LLC, has exercised its over-allotment option to purchase an additional 122,500 common shares from the Akers Biosciences at $1.20 per share with the issuance of a further 61,250 warrants with an exercise price of $1.50 (the Warrants).
BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand.
Weifa has made a deal with New Zealand’s AFT Pharmaceuticals according to which it will sell drugs for pain relief and fever symptoms in the Nordic region (Norway, Sweden, Denmark, Finland and Iceland).
Mainstay Medical International has applied for ReActiv8 to be admitted to the Australian Register of Therapeutic Goods (ARTG) which would…